|
Dec 22
|
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
|
|
Nov 27
|
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
|
|
Nov 27
|
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
|
|
Nov 7
|
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
|
|
Apr 26
|
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
|